Lifeloc Technologies Reports Increased Net Loss and Declining Revenues in Q2 2025

Lifeloc Technologies, Inc. reported a net loss of $393,639 for the second quarter of 2025, a 32% increase from the net loss of $297,988 in the same period of 2024. Total revenues for the quarter were $2,219,376, down 7% from $2,387,330 a year earlier. The decline in revenue was primarily attributed to a decrease in product sales, which fell to $2,191,260 from $2,370,433, reflecting the absence of several larger orders and ongoing inflationary pressures affecting customer budgets. Despite a slight increase in royalties and rental income, the overall financial performance was impacted by reduced sales volume.

For the first half of 2025, Lifeloc's total revenues decreased by 1% to $4,496,410 compared to $4,540,773 in the same period of 2024. Product sales for the six months were $4,454,307, a marginal decline from $4,504,867. The company reported a gross profit of $1,833,165, which was relatively stable compared to $1,828,903 in the prior year. Operating expenses decreased slightly, but the company still incurred a net loss of $686,325 for the six months, compared to a loss of $581,794 in 2024.

In terms of operational developments, Lifeloc has focused on expanding its product offerings, particularly in the alcohol and drug detection markets. The company is advancing its SpinDx™ technology, which is expected to launch in stages starting in 2026. This technology aims to provide rapid, on-site drug testing capabilities, enhancing Lifeloc's competitive position in the market. The company also emphasized the importance of high-quality training, which has been integrated into its product offerings through Lifeloc University.

Lifeloc's balance sheet as of June 30, 2025, showed total assets of $8,623,154, a decrease from $8,724,769 at the end of 2024. Current liabilities increased to $956,094 from $743,575, primarily due to higher accounts payable and accrued expenses. The company’s cash and cash equivalents stood at $995,750, down from $1,243,746 at the end of the previous fiscal year. The increase in liabilities and decrease in cash reserves indicate a tightening liquidity position, which may necessitate further capital management strategies.

Looking ahead, Lifeloc anticipates that its installed base of breathalyzers will grow as awareness of alcohol-related risks increases. The company plans to enhance its marketing efforts and expand its sales network to drive revenue growth. However, it acknowledges the potential for continued operating losses as it invests in the commercialization of new products. The outlook remains cautious, with management emphasizing the need for effective cost management and the successful introduction of SpinDx™ to achieve profitability in the future.